Several other equities analysts also recently commented on IKNA. HC Wainwright decreased their price target on shares of Ikena Oncology from $18.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Wedbush initiated coverage on shares of Ikena Oncology in a report on Thursday, September 21st. They set an “outperform” rating and a $11.00 target price on the stock.
Ikena Oncology Price Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $46,000. Wells Fargo & Company MN boosted its holdings in shares of Ikena Oncology by 2,913.6% in the 2nd quarter. Wells Fargo & Company MN now owns 8,227 shares of the company’s stock valued at $54,000 after purchasing an additional 7,954 shares in the last quarter. Millennium Management LLC bought a new position in shares of Ikena Oncology in the 4th quarter valued at $27,000. American International Group Inc. acquired a new position in shares of Ikena Oncology during the 2nd quarter worth $67,000. Finally, SG Americas Securities LLC acquired a new position in shares of Ikena Oncology during the 3rd quarter worth $46,000. Institutional investors and hedge funds own 86.01% of the company’s stock.
About Ikena Oncology
Ikena Oncology, Inc operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway.
- Five stocks we like better than Ikena Oncology
- 5 Top Rated Dividend Stocks to Consider
- Amazon, Target, Walmart in a race for fastest delivery
- What is the Dow Jones Industrial Average (DJIA)?
- Palo Alto Networks: the one security stock to rule them all
- Retail Stocks Investing, Explained
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.